{"id":"W4220729116","doi":"10.1158/1538-7445.sabcs21-ot2-11-05","title":"Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable <i>ESR1</i>m who have not experienced disease progression on first-line therapy","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Metastatic breast cancer; Cancer; Oncology; Breast cancer; Aromatase inhibitor; Aromatase; Estrogen receptor; Fulvestrant; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008294403,0.0004661326,0.0008528636,0.0004537431,0.0004850019,0.00007073532,0.0003624354,0.00003147886,0.0002096149],"category_scores_gemma":[0.00003473227,0.0002473764,0.00003024683,0.001451785,0.0005268956,0.0003310262,0.0001283783,0.0007402736,3.704809e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008114482,"about_ca_system_score_gemma":0.0009097155,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002906113,"about_ca_topic_score_gemma":0.009669812,"domain_scores_codex":[0.9950516,0.0004994205,0.0005761858,0.0009099012,0.002216613,0.000746262],"domain_scores_gemma":[0.9976597,0.0004573647,0.0003167138,0.0006908473,0.0005003656,0.0003749754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5440634,0.01053355,0.3953563,0.0003173358,0.000305775,0.0003606192,0.01846357,0.01070161,0.000661135,0.000002695936,0.00003697899,0.01919699],"study_design_scores_gemma":[0.1475804,0.01954444,0.8121471,0.003740319,0.0001020815,0.00001933558,0.01222967,0.0003523241,0.0035788,0.000006714266,0.0001884736,0.0005103305],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884363,0.0002308265,0.00003718413,0.001588976,0.0000249288,0.009077579,0.0005600829,0.00003688844,0.000007263597],"genre_scores_gemma":[0.9937757,0.00005782913,0.0001471876,0.0001352828,0.0000303746,0.005609354,0.00009311693,0.00010599,0.0000451206],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4167908,"threshold_uncertainty_score":0.9999979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06113314548597167,"score_gpt":0.4015729937799294,"score_spread":0.3404398482939577,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}